[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 444,477
  • Shares Outstanding, K 52,353
  • Annual Sales, $ 9,680 K
  • Annual Income, $ -244,090 K
  • EBIT $ -119 M
  • EBITDA $ -115 M
  • 60-Month Beta -0.25
  • Price/Sales 44.82
  • Price/Cash Flow N/A
  • Price/Book 1.43

Options Overview Details

View History
  • Implied Volatility 89.27% (-55.17%)
  • Historical Volatility 58.16%
  • IV Percentile 40%
  • IV Rank 14.43%
  • IV High 339.95% on 11/19/25
  • IV Low 47.00% on 12/17/25
  • Expected Move (DTE 29) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,158
  • Volume Avg (30-Day) 264
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 14,973
  • Open Int (30-Day) 12,193
  • Expected Range 8.61 to 8.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 3
  • High Estimate $-0.38
  • Low Estimate $-0.40
  • Prior Year $-1.86
  • Growth Rate Est. (year over year) +79.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.73 +11.38%
on 06/11/26
10.26 -16.08%
on 05/27/26
-0.98 (-10.22%)
since 05/18/26
3-Month
7.73 +11.38%
on 06/11/26
11.80 -27.03%
on 05/08/26
+0.02 (+0.23%)
since 03/18/26
52-Week
5.64 +52.66%
on 06/20/25
11.80 -27.03%
on 05/08/26
+2.86 (+49.74%)
since 06/18/25

Most Recent Stories

More News
Prothena: Q1 Earnings Snapshot

Prothena: Q1 Earnings Snapshot

PRTA : 8.77 (+3.30%)
Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates...

PRTA : 8.77 (+3.30%)
Prothena: Can Partners Carry the Narrative Through Another Year Without Internal Catalysts?

Barchart Research What to Expect from PRTA Earnings PRTA Generated May 6, 2026 Current Price $11.18 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 2.81% Prothena: Can Partners Carry the...

PRTA : 8.77 (+3.30%)
Prothena to Report First Quarter 2026 Financial Results on May 7

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 8.77 (+3.30%)
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Coramitug is being evaluated by...

PRTA : 8.77 (+3.30%)
Prothena Announces Leadership Team Updates

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced updates...

PRTA : 8.77 (+3.30%)
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner...

PRTA : 8.77 (+3.30%)
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Prothena has now earned $150 million...

PRTA : 8.77 (+3.30%)
Prothena Announces up to $100 Million Share Repurchase Plan

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 8.77 (+3.30%)
Prothena: Q4 Earnings Snapshot

Prothena: Q4 Earnings Snapshot

PRTA : 8.77 (+3.30%)

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 9.01
2nd Resistance Point 8.86
1st Resistance Point 8.68
Last Price 8.77
1st Support Level 8.35
2nd Support Level 8.20
3rd Support Level 8.02

See More

52-Week High 11.80
Fibonacci 61.8% 9.45
Last Price 8.77
Fibonacci 50% 8.72
Fibonacci 38.2% 7.99
52-Week Low 5.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.